Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 3c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $13.67 million versus the consensus estimate of $11.19 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• BofA Securities Starts APL Apollo Tubes Ltd (APAT:IN) at Buy
• RBC Capital Starts Greenfire Resources (GFR:CN) at Sector Perform
• Nayax adds AI features to its MoMa app for vending operators